Area of research
Cardiology and Cardiovascular Medicine · Epidemiology
Research interest
Research interests include Medicine, Cardiology, Internal medicine, Hypertrophic cardiomyopathy, Placebo, and Ejection fraction.
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial
Aficamten and Cardiopulmonary Exercise Test Performance
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3